China Medical System (CHSYF) announced that its subsidiary, Dermavon Holdings has obtained the relevant licensing rights to the oral JAK1 inhibitor povorcitinib, which has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China, with a proposed indication for adult patients with non-segmental vitiligo. This certification has the potential to accelerate the development and review process of the Product.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHSYF:
- China Medical System’s Breakthrough in Vitiligo Treatment with Povorcitinib
- China Medical System announces NMPA acceptance of Y-3 NDA
- China Medical System’s Innovative Stroke Treatment Gains Regulatory Acceptance
- China Medical System Holdings Maintains Stable Share Capital in November 2025
- China Medical System announces NMPA acceptance of MG-K10 NDA